Vendor comparison · 2026
VIP vendors: 14 compared on COAs and price
Tissue & recoveryAlso known as Vasoactive intestinal peptide, Aviptadil
Evidence tier
Regulator-reviewed human evidence
2 human trials · 1 review · 1 observational
- Vendors carrying it
- 14
- 13 with a listed price
- Vendors with checkable COAs
- 6
- 6 publish any certificate
- Lots tested
- 6
- 6 naming a checkable lab
- Independent assays
- 0
- none on file yet
- Newest assay
- 18 Sept 2026
- oldest 18 Mar 2026
- Laboratories named
- 4
- most often Freedom Diagnostics Testing
- Median label gap
- 5.6%
- 50% of lots within 5% of label
- Median purity
- 99.71%
- 6 of 6 lots at 99% or above
- Lowest price per mg
- $4.20
- peer median $8.40
- Publications located
- 15k
- researched since 1970
Source: PepIndex, an independent index of research-peptide vendors. No vendor can pay for a rank, every score is computed by a published formula, and every figure links to the document it was read from.
Next Gen Peptides has the most checkable VIP testing in this index: 1 lot assayed by ILS Laboratories, the newest on 21 Apr 2026. The lowest listed price is $4.20 per mg at Ascend Science, against a peer median of $8.40. 14 vendors carrying VIP are compared below. 6 publish at least one certificate naming a checkable laboratory, 6 lot records are on file, and none is an independently commissioned assay. Figures are PepIndex's own: it is an independent index of research-peptide vendors, no vendor can pay for a rank, and each figure links to the certificate it was read from.
Every vendor carrying VIP
| # | Vendor | Score here | Price / mg | Lots | Newest test | Laboratory | Mean purity | Label gap | Reports |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Next Gen PeptidesISO/IEC 17025 | 93.697% | $4.50 (54%) | 1 / 1 | ILS Laboratories | 100.0% | 4.9% | ||
| 2 | Ascend ScienceISO/IEC 17025 | 93.494% | $4.20 (50%) | 0 | — | — | — | — | |
| 3 | Amino ClubISO/IEC 17025Age-gated COAs | 92.598% | $5.00 (60%) | 0 | — | — | — | — | |
| 4 | PeptidePlugs | 9094% | $6.00 (71%) | 1 / 1 | Freedom Diagnostics Testing | 99.8% | 6.3% | ||
| 5 | Ascension Peptides | 82.489% | $8.00 (95%) | 1 / 1 | Kovera Labs | 99.8% | 14.7% | ||
| 6 | Protide HealthAge-gated COAs | 80.292% | $7.50 (89%) | 0 | — | — | — | — | no reportVisit site |
| 7 | One Aminos | 7889% | $10.00 (119%) | 1 / 1 | United Laboratories | 99.6% | 2.0% | ||
| 8 | Simple Peptide | 74.392% | $10.40 (124%) | 1 / 1 | Freedom Diagnostics Testing | 99.2% | 11.4% | ||
| 9 | Northline LabsISO/IEC 17025 | 73.595% | — | 1 / 1 | ILS Laboratories | 99.7% | 2.8% | ||
| 10 | True Research Labs | 6468% | $8.40 (100%) | 0 | — | — | — | — | no reportVisit site |
| 11 | Licensed Peptides | 60.687% | $25.80 (250%) | 0 | — | — | — | — | no reportVisit site |
| 12 | GenX Peptides | 59.669% | $11.00 (131%) | 0 | — | — | — | — | no reportVisit site |
| 13 | BioLongevity Labs | 54.572% | $14.99 (179%) | 0 | — | — | — | — | no reportVisit site |
| 14 | Biotech Peptides | 53.960% | $11.83 (141%) | 0 | — | — | — | — | no reportVisit site |
Independent assays
No independently commissioned assay of VIP is on file. All 6 records below were published by the vendor that sells the product, naming the laboratory shown. PepIndex does not yet commission its own assays, so nothing on this page establishes what is in a vial beyond the vendor’s own certificate. A record moves into this section the moment an assay commissioned by anyone other than the seller is indexed.
What the certificates show
6 of 6 lots at 99% or above; median 99.71%.
| Range | lots |
|---|---|
| <95% | 0 |
| 95–97% | 0 |
| 97–98% | 0 |
| 98–99% | 0 |
| 99–99.5% | 1 |
| ≥99.5% | 5 |
50% of lots within 5% of the labelled mass; median gap 5.6%.
| Range | lots |
|---|---|
| ≤2% | 1 |
| 2–5% | 2 |
| 5–10% | 1 |
| 10–20% | 2 |
| >20% | 0 |
13 vendors, $4.20 to $25.80; median $8.40.
| Range | vendors |
|---|---|
| $0–$5.00 | 2 |
| $5.00–$10.00 | 5 |
| $10.00–$15.00 | 5 |
| $15.00–$20.00 | 0 |
| $20.00–$25.00 | 0 |
| $25.00–$30.00 | 1 |
Purity and mass are read from each certificate as published; the label gap is |labeled − assayed| ÷ labeled. Every value behind these bars is in the certificate table below.
Laboratories used
| Laboratory | Lots | Vendors | Share | Verify |
|---|---|---|---|---|
| Freedom Diagnostics TestingUS | 2 | 2 | 33% | Public lookup |
| ILS LaboratoriesUS | 2 | 2 | 33% | Public lookup |
| Kovera Labs | 1 | 1 | 17% | No public lookup found |
| United LaboratoriesIN | 1 | 1 | 17% | Public lookup |
Every certificate record
| Vendor | Lot | Tested | Lab | Labeled | Assayed | Discrepancy | Purity | Report |
|---|---|---|---|---|---|---|---|---|
 One Aminos | VIP5-091526 | United Laboratories | 5 mg | 5.1 mg | 2.0% | 99.6% | Vendor-published | |
| NLNorthline Labs | NLL-8713624 | ILS Laboratories | 10 mg | 10.28 mg | 2.8% | 99.7% | Vendor-published | |
 PeptidePlugs | 138-01-SM | Freedom Diagnostics Testing | 10 mg | 9.37 mg | 6.3% | 99.8% | Vendor-published | |
 Ascension Peptides | 52-05260628 | Kovera Labs | 10 mg | 11.47 mg | 14.7% | 99.8% | Vendor-published | |
 Next Gen Peptides | VP10-03 | ILS Laboratories | 10 mg | 10.49 mg | 4.9% | 100.0% | Vendor-published | |
 Simple Peptide | VP5-032026-1 | Freedom Diagnostics Testing | 5 mg | 4.43 mg | 11.4% | 99.2% | Vendor-published |
Score breakdown
The score has two halves: the research base — how long the compound has been studied and how much has been published — and the quality of the evidence the market produces for it, aggregated across every vendor that carries it: assayed purity, lot-to-lot consistency, readable third-party certificates and those vendors’ review record. It measures the evidence base, not the merits or safety of the substance.
Studied since 1970 — 56 years of published research
How long the compound has been studied. Fifteen years or more of published literature earns full marks; a newer compound earns less.
15,132 publications indexed in PubMed
The volume of published literature located. Full marks at fifty or more publications.
Mean assayed purity 99.7% across 6 certificates
Average assayed purity on the certificates published by vendors that carry this compound. Full marks at 99.5%+, nothing at 95% or below.
±0.24 pts purity across lots, mean label deviation 7.0%
How tightly assayed purity and labeled-versus-actual mass hold across different lots. Rewards reproducible manufacturing.
14 of 14 listing vendors publish an accessible certificate policy
Whether the vendors carrying this compound publish per-lot certificates anyone can read without an account.
6 of 6 certificates from a recognised independent lab
Share of certificates issued by a recognised third-party testing lab rather than an unnamed or self-named one.
What is VIP?
Vasoactive intestinal peptide, a 28–amino-acid signalling peptide with roles in vasodilation, secretion and inflammation. Its related drug is known as aviptadil.
Studied in published research for inflammation, vasodilation and immune regulation.
Regulatory status
Labeled by vendors for laboratory research use only. Not approved as a medicine in the United States, United Kingdom, or European Union.
What the research examines
The areas of published research this compound appears in. These describe what the literature has studied — never a claim of benefit, effect or suitability for any use.
Published research
The related drug aviptadil has been studied in human trials. PepIndex does not evaluate clinical significance and does not describe administration.
- Vasoactive intestinal peptide — Journal of endocrinological investigation (1986)
Peer-reviewed article indexed in PubMed, published in Journal of endocrinological investigation (1986).
- Therapeutic potential of vasoactive intestinal peptide and its receptor VPAC2 in type 2 diabetes — Frontiers in endocrinology (2022)
Peer-reviewed article indexed in PubMed, published in Frontiers in endocrinology (2022).
- Vasoactive intestinal peptide in the heart — Annals of the New York Academy of Sciences (1988)
Peer-reviewed article indexed in PubMed, published in Annals of the New York Academy of Sciences (1988).
- Recent advances in vasoactive intestinal peptide physiology and pathophysiology: focus on the gastrointestinal system — F1000Research (2019)
Peer-reviewed article indexed in PubMed, published in F1000Research (2019).
- Vasoactive intestinal peptide. Messenger in a neuroimmune axis — Annals of the New York Academy of Sciences (1990)
Peer-reviewed article indexed in PubMed, published in Annals of the New York Academy of Sciences (1990).
- Vasoactive Intestinal Peptide (VIP) Nanoparticles for Diagnostics and for Controlled and Targeted Drug Delivery — Advances in protein chemistry and structural biology (2015)
Peer-reviewed article indexed in PubMed, published in Advances in protein chemistry and structural biology (2015).
- Vasoactive intestinal peptide in the lung — Annals of the New York Academy of Sciences (1988)
Peer-reviewed article indexed in PubMed, published in Annals of the New York Academy of Sciences (1988).
- Vasoactive intestinal peptide in the immune system: potential therapeutic role in inflammatory and autoimmune diseases — Journal of molecular medicine (Berlin, Germany) (2002)
Peer-reviewed article indexed in PubMed, published in Journal of molecular medicine (Berlin, Germany) (2002).
Indexed studies4 human-evidence of 4
- Intravenous aviptadil and remdesivir for treatment of COVID-19-associated hypoxaemic respiratory failure in the USA (TESICO): a randomised, placebo-controlled trial — Human — controlled trial, 2023
There is a clinical need for therapeutics for COVID-19 patients with acute hypoxemic respiratory failure whose 60-day mortality remains at 30-50%. Aviptadil, a lung-protective neuropeptide, and remdesivir, a nucleotide prodrug of an adenosine analog, were compared with placebo among patients with COVID-19 acute hypoxaemic respiratory failure. TESICO was a randomised trial of aviptadil and remdesivir versus placebo at 28 sites in the USA. Hospitalised adult patients were eligi…
- Brief Report: Rapid Clinical Recovery From Critical Coronavirus Disease 2019 With Respiratory Failure in a Pregnant Patient Treated With IV Vasoactive Intestinal Peptide — Case report, 2022
Aviptadil, a synthetic form of human vasoactive intestinal peptide, has entered clinical trials to treat critical coronavirus disease 2019 pneumonia with respiratory failure. Vasoactive intestinal peptide protects the lung against a broad array of injuries by binding to the vasoactive intestinal peptide receptor 1 receptor of alveolar type II cells, the cells that severe acute respiratory syndrome coronavirus 2 binds to. As the role of Aviptadil in treating pregnant patients …
- The Use of IV Vasoactive Intestinal Peptide (Aviptadil) in Patients With Critical COVID-19 Respiratory Failure: Results of a 60-Day Randomized Controlled Trial — Human — controlled trial, 2022
Respiratory failure is a lethal complication of COVID-19 that has remained resistant to drug therapy. Vasoactive intestinal peptide (VIP) is shown in nonclinical studies to upregulate surfactant production, inhibit cytokine synthesis, prevent cytopathy, and block replication of the severe acute respiratory syndrome coronavirus 2 virus in pulmonary cells. The study aims to determine whether Aviptadil (synthetic VIP) can improve survival and recovery in patients with COVID-19 r…
- Erectile dysfunction: a global review of intracavernosal injectables — Systematic review, 2019
Data assessing the effectiveness of intracavernosal injections (ICIs) for the treatment of erectile dysfunction (ED) are limited. This study evaluates intracavernosal injectable therapies for ED and reviews available guidelines that inform clinical practice. A systematic search using electronic databases (Medline, Pubmed) was performed for studies investigating injectable management strategies for ED published after 1990. Primary outcome measures were to comparatively evaluat…
Evidence digest
What the research on VIP actually shows
The indexed literature on VIP includes human clinical or observational records (4 human-clinical or observational records). This digest describes the shape of that evidence and links the records behind it. It does not judge whether VIP is safe or effective for any purpose, and nothing here is medical advice — the material sold by the vendors in this index is labeled for laboratory research use only.
3 things the literature does not establish →
PepIndex describes what literature exists. We do not interpret it, assess clinical significance, or publish quantities, protocols or instructions for use.